Tratamento da UCE refratária aos anti-histamínicos e na impossibilidade do omalizumabe, nos adultos
Treatment of CSU refractory to antihistamines and in the impossibility of omalizumab therapy in adults
Bruna Gehlen; Mariana Mousinho-Fernandes; Paula Natassya Argolo; Grazielly de Fátima Pereira; Jorge Kalil; Antônio Abilio Motta; Rosana Câmara Agondi
Resumo
Há o empenho contínuo de especialistas no desenvolvimento de tratamentos resolutivos ou eficazes nos controles das doenças, no entanto, a entidade urticária crônica espontânea (UCE), quando refratária à primeira linha de tratamento, os anti-histamínicos, apresenta um prognóstico desfavorável. Existe um arsenal de medicamentos biológicos disponíveis já consolidados como eficazes e seguros, porém eventualmente nos defrontamos com a inacessibilidade a estes medicamentos, devido aos custos dos mesmos e aos trâmites necessários para dar início ao tratamento. Tais fatos fundamentam a discussão sobre terapias alternativas com outros fármacos, visando manter o manejo adequado da doença e a qualidade de vida dos pacientes.
Palavras-chave
Abstract
Specialists have made a continuous effort for the development of effective treatments for disease control; however, chronic spontaneous urticaria (CSU), when refractory to the first line of treatment, ie, antihistamines, has an unfavorable prognosis. There are biological medicines available, which have been consolidated as effective and safe, but we are occasionally faced with a lack of access to these medicines due to their costs and the necessary procedures to start treatment. Such facts support the discussion about alternative therapies with other drugs, aiming at maintaining the adequate management of the disease and the quality of life of patients.
Keywords
References
1. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, BallmerWeber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393-414.
2. Maurer M, Church MK, Marsland AM, Sussman G, Siebenhaar F, Vestergaard FC, et al. Questions and answers in chronic urticaria: where do we stand and where do we go? J Eur Acad Dermatol Venereol. 2016;30(Suppl 5):7-15.
3. Bracken SJ, Abraham S, MacLeod AS. Autoimmune theories of chronic spontaneous urticaria. Front Immunol. 2019;10:627.
4. Church MK, Maurer M, Simons FER, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Risk of firstgeneration H1-antihistamines: a GA2LEN position paper. Allergy. 2010;65:459‑66.
5. Church MK. Does antihistamine up-dosing solve chronic spontaneous urticaria? Curr Treat Options Allergy. 2016;3:416-22.
6. Vestergaard C, Toubi E, Maurer M, Triggiani M, Ballmer-Weber B, Marsland A, et al. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion. Eur J Dermatol. 2017;27(1):10-19.
7. Parisi GF, Leonardi S, Ciprandi G, Corsico A, Licari A, del Giudice MM, et al. Cetirizine use in childhood: an update of a friendly 30‑year drug. Clin Mol Allergy. 2020;18:2.
8. Baharudin A, Abdul Latiff AH, Woo K, Yap FBB, Tang IP, Leong KF, et al. Using patient profiles to guide the choice of antihistamines in the primary care setting in Malaysia: expert consensus and recommendations. Ther Clin Risk Manag. 2019;15:1267-75.
9. Gasser P, Tarchevskaya SS, Guntern P, Brigger D, Ruppli R, Zbären N, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11:165.
10. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/ spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101-9.
11. Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Baskan EB, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135:67-75.
12. Maurer M, Vena GA, Cassano N, Zuberbier T. Current and future therapies for treating chronic spontaneous urticaria. Expert Opin Pharmacother. 2016;17:1131-9.
13. Deza G, Ricketti PA, Giménez-Arnau AM, Casale TB. Emerging biomarkers and therapeutic pipelines for chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2018;6:1108-17.
14. Incorvaia C, Mauro M, Makri E, Leo G, Ridolo E. Two decades with omalizumabe: what we still have to learn. Biologics: Targets and Therapy. 2018;12:135-42.
15. Francés L, Leiva-Salinas M, Silvestre JF. Omalizumabe in the treatment of chronic urticaria. Actas Dermosifiliogr. 2014;105:45‑52.
16. Zhao ZT, Ji CM, Meng L, Hawro T, Wei JF, Maurer M. Omalizumab for the treatment of chronic spontaneous urticaria: a metaanalysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137:1742‑50.
17. Kaplan AP. Treatment of urticaria: a clinical and mechanistic approach. Curr Opin Allergy Clin Immunol. 2019;19:387-92.
18. Giménez Arnau AM, Santiago AV, Tomás JB, Presa IJ, Horrillo ML, Miguel FJM, et al. Therapeutic strategy according to the differences in response to omalizumab in patients with chronic spontaneous urticaria. J Investig Allergol Clin Immunol. 2019;29:338-48.
19. Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma B, Raimundo K, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137:474-81.
20. Holm JG, Ivyanskiy I, Thomsen SF. Use of nonbiologic treatments in antihistamine refractory chronic urticaria: a review of published evidence. J Dermatol Treat. 2018;29:80-97.
21. Khan DA. Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use. J Allergy Clin Immunol Pract. 2013;1:433-40.
22. Vena GA, Maurer M, Cassano N, Zuberbier T. Alternative treatments for chronic spontaneous urticaria beyond the guideline algorithm. Curr Opin Allergy Clin Immunol. 2017;17:278-85.
23. Grattan CEH, O’Donnell BFO, Francis DM, Niimi N, Barlow RJ, Seed PT, et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol. 2000;143:365-72.
24. Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol. 2010;63:925-46.
25. Kulthanan K, Subchookul C, Hunnangkul S, Chularojanamontri L, Tuchinda P. Factors predicting the response to cyclosporin treatment in patients with chronic spontaneous urticaria: a systematic review. Allergy Asthma Immunol Res. 2019;11:736-55.
26. Amber T, Tabassum S. Cyclosporin in dermatology: a practical compendium. Dermatol Ther. 2020;33:e13934.
27. Stanaland BE. Treatment of patients with chronic idiopathic urticaria. Clin Rev Allergy Immunol. 2002;23:233-40.
28. da Silva NL, Damayanthi H, Rajapakse AC, Rodrigo C, Rajapakse S. Lukotriene receptor antagonists for chronic urticaria: a systematic review. Allergy Asthma Clin Immunol. 2014;10:24.
29. Sarkar TK, Sil A, Pal S, Ghosh C, Das NK. Efectiveness and safety of levocetirizine 10 mg versus a combination of levocetirizine 5 mg and montelukast 10 mg in chronic urticaria resistant to levocetirizine 5 mg: A double-blind, randomized, controlled trial. Indian J Dermatol Venereol Leprol. 2017;83:561-8.
30. Akenroye AT, McEwan C, Saini SS. Montelukast reduces symptom severity and frequency in patients with angioedema-predominat chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2018;6:1403-5.
31. Haarman MG, van Hunsel F, de Vries TW. Adverse drug reactions of montelukast in children and adults. Pharmacol Res Per. 2017;5:e00341.
32. Iweala OI, Copenhaver C, Wu EY, Moran TP. Hydroxychloroquine as a steroid-sparing agente in an infant with chronic urticaria. Ann Allergy Asthma Immunol. 2018;120:102-4.
33. Boonpiyathad T, Sangasapaviliya A. Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous urticaria, randomized single-blinded placebo-controlled trial and an open label comparison study. Eur Ann Allergy Clin Immunol. 2017;49:220‑4.
34. Seth S, Khan DA. The comparative safety of multiple alternative agentes in refractory chronic urticaria patients. J Allergy Clin Immunol Pract. 2017;5:165-70.e.2.
35. Antia C, Baquerizo K, Korman A, Alikhan A, Bernstein JA. Urticaria: A comprehensive review: treatment of chronic urticaria, special populations, and disease outcomes. J Am Acad Dermatol. 2018;79:617-3.
36. Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: an evidence-based review, part 1. Ann Allergy Asthma Immunol. 2008;100:403-12.
37. de Montojoye L, Herman A, Nicolas JF, Baeck M. Treatment of chronic spontaneous urticaria: immunomodulatory approaches. Clin Immunol. 2018;190:53-63.
38. Liang SE, Hoffmann R, Peterson E, Soter NA. Use of dapsone in the treatment of chronic idiopathic and autoimmune urticaria. JAMA Dermatology. 2019;155:90-5.
39. Morgan M, Cooke A, Rogers L, Adams-Huet B, Khan DA. Doubleblind placebo controlled trial of dapsone in antihistamine refractory idiopathic urticaria. J Allergy Clin Immunol. 2014;2:601-6.
40. Mehta A, Godse K, Patil S, Nadkarni N, Gautam M. Treatment of refractory chronic urticaria. Indian J Dermatol. 2015;60:230-7.
Submitted date:
02/01/2021
Accepted date:
04/21/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email